E-Prescription System Funding Transparency Recommended In Pfizer Study
This article was originally published in The Pink Sheet Daily
Executive Summary
Electronic prescribing systems should be designed to prevent the promotion of pharmaceuticals for non-clinical reasons, such as the benefit to third-party entities that may fund the system, a RAND expert panel suggests in a report commissioned by Pfizer.
You may also be interested in...
E-Prescribing Systems Should Provide Individualized Cost Data, Pfizer Says
Specific patient information should be provided at the point of care, Pfizer tells the HHS subcommittee charged with setting e-prescribing standards. Express Scripts prefers providing formulary and copay data, rather than actual cost information.
E-Prescribing Systems Should Provide Individualized Cost Data, Pfizer Says
Specific patient information should be provided at the point of care, Pfizer tells the HHS subcommittee charged with setting e-prescribing standards. Express Scripts prefers providing formulary and copay data, rather than actual cost information.
E-Prescribing Meeting By HHS Cmte. Set For May 25-27
Network providers RxHub and SureScripts are expected to testify. The National Health Statistics/Standards Subcommittee is charged with developing principles for electronic prescribing under the Medicare drug benefit.